Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:S-butyl-DL-homocysteine (S,R)-sulfoximine
go back to main search page
Accession:CHEBI:28714 term browser browse the term
Definition:A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.
Synonyms:related_synonym: (2RS)-2-amino-4-(S-butylsulfonimidoyl)butanoic acid;   (2RS)-2-amino-4-(S-butylsulfonimidoyl)butyric acid;   DL-butathionine-(S,R)-sulfoximine;   DL-buthionine sulfoximine;   Formula=C8H18N2O3S;   InChI=1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12);   InChIKey=KJQFBVYMGADDTQ-UHFFFAOYSA-N;   SMILES=CCCCS(=N)(=O)CCC(N)C(O)=O;   buthionine sulfoximine;   buthionine sulphoximine
 alt_id: CHEBI:22039;   CHEBI:8953
 xref: Beilstein:236716;   CAS:5072-26-4;   KEGG:C04543;   LINCS:LSM-36606
 xref_mesh: MESH:D019328
 xref: PMID:27008382;   PMID:27764704;   PMID:29127710;   PMID:31302132;   PMID:32965035;   PMID:34036678;   Wikipedia:Buthionine_sulfoximine



show annotations for term's descendants           Sort by:
S-butyl-DL-homocysteine (S,R)-sulfoximine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc1 ATP-binding cassette, sub-family C member 1 affects localization
multiple interactions
ISO Buthionine Sulfoximine affects the localization of ABCC1 protein mutant form
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [ABCC1 results in decreased susceptibility to arsenite]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [ABCC1 results in decreased susceptibility to monomethylarsonous acid analog]; Buthionine Sulfoximine analog inhibits the reaction [Acetylcysteine promotes the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]]; Buthionine Sulfoximine inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Buthionine Sulfoximine inhibits the reaction [ABCC1 results in decreased susceptibility to arsenite]; Buthionine Sulfoximine inhibits the reaction [ABCC1 results in decreased susceptibility to methylarsine analog]
CTD PMID:15180633 PMID:15473893 PMID:15581632 PMID:21918036 NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
JBrowse link
G Acin1 apoptotic chromatin condensation inducer 1 increases expression ISO Buthionine Sulfoximine results in increased expression of ACIN1 protein CTD PMID:23736079 NCBI chr14:54,879,618...54,924,422
Ensembl chr14:54,879,618...54,924,388
JBrowse link
G Aco2 aconitase 2, mitochondrial decreases activity EXP Buthionine Sulfoximine results in decreased activity of ACO2 protein CTD PMID:18552690 NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334
JBrowse link
G Actb actin, beta decreases expression EXP Buthionine Sulfoximine results in decreased expression of ACTB mRNA CTD PMID:15878706 NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509
JBrowse link
G Add3 adducin 3 increases expression EXP Buthionine Sulfoximine results in increased expression of ADD3 mRNA CTD PMID:15878706 NCBI chr19:53,128,874...53,235,518
Ensembl chr19:53,128,874...53,235,830
JBrowse link
G Adh1 alcohol dehydrogenase 1 (class I) multiple interactions ISO Buthionine Sulfoximine promotes the reaction [Ethanol results in increased expression of ADH1 mRNA] CTD PMID:20705415 NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459
JBrowse link
G Aimp1 aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 increases expression EXP Buthionine Sulfoximine results in increased expression of AIMP1 mRNA CTD PMID:15878706 NCBI chr 3:132,366,259...132,390,151
Ensembl chr 3:132,366,242...132,390,131
JBrowse link
G Akt1 thymoma viral proto-oncogene 1 multiple interactions EXP Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium results in increased phosphorylation of AKT1 protein] CTD PMID:24449419 NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
JBrowse link
G Alad aminolevulinate, delta-, dehydratase decreases activity ISO Buthionine Sulfoximine results in decreased activity of ALAD protein CTD PMID:21620807 NCBI chr 4:62,422,762...62,438,300
Ensembl chr 4:62,427,406...62,438,155
JBrowse link
G Alas1 aminolevulinic acid synthase 1 multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [1,2,4-trichlorobenzene results in increased activity of ALAS1 protein] CTD PMID:11996131 NCBI chr 9:106,110,654...106,125,153
Ensembl chr 9:106,110,654...106,125,853
JBrowse link
G Alb albumin multiple interactions ISO [Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of ALB mRNA CTD PMID:23288050 NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
JBrowse link
G Ambp alpha 1 microglobulin/bikunin precursor multiple interactions ISO [Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of AMBP mRNA CTD PMID:23288050 NCBI chr 4:63,061,512...63,072,409
Ensembl chr 4:63,061,512...63,073,036
JBrowse link
G Apex1 apurinic/apyrimidinic endonuclease 1 increases expression ISO Buthionine Sulfoximine results in increased expression of APEX1 protein CTD PMID:23736079 NCBI chr14:51,162,406...51,164,645
Ensembl chr14:51,162,425...51,164,596
JBrowse link
G Apoh apolipoprotein H multiple interactions ISO [Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of APOH mRNA CTD PMID:23288050 NCBI chr11:108,286,123...108,305,222
Ensembl chr11:108,234,180...108,305,222
JBrowse link
G App amyloid beta precursor protein multiple interactions ISO (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein CTD PMID:19850110 NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
JBrowse link
G Arnt aryl hydrocarbon receptor nuclear translocator decreases expression ISO Buthionine Sulfoximine results in decreased expression of ARNT protein CTD PMID:16880289 NCBI chr 3:95,341,674...95,404,551
Ensembl chr 3:95,341,699...95,404,551
JBrowse link
G Atp2a2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 decreases expression EXP Buthionine Sulfoximine results in decreased expression of ATP2A2 protein CTD PMID:18552690 NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288
JBrowse link
G Atp5f1b ATP synthase F1 subunit beta increases expression EXP Buthionine Sulfoximine results in increased expression of ATP5F1B mRNA CTD PMID:15878706 NCBI chr10:127,919,176...127,926,257
Ensembl chr10:127,919,142...127,926,260
JBrowse link
G Atxn1 ataxin 1 affects localization
multiple interactions
ISO Buthionine Sulfoximine affects the localization of ATXN1 protein mutant form
Buthionine Sulfoximine promotes the reaction [Hydrogen Peroxide affects the localization of ATXN1 protein mutant form]; Buthionine Sulfoximine promotes the reaction [tert-Butylhydroperoxide affects the localization of ATXN1 protein mutant form]
CTD PMID:12893416 NCBI chr13:45,703,231...46,118,467
Ensembl chr13:45,703,231...46,118,484
JBrowse link
G Axl AXL receptor tyrosine kinase increases expression EXP Buthionine Sulfoximine results in increased expression of AXL mRNA CTD PMID:15878706 NCBI chr 7:25,455,925...25,488,502
Ensembl chr 7:25,456,698...25,488,130
JBrowse link
G Azin1 antizyme inhibitor 1 decreases expression EXP Buthionine Sulfoximine results in decreased expression of AZIN1 mRNA CTD PMID:15878706 NCBI chr15:38,487,674...38,523,506
Ensembl chr15:38,487,671...38,519,510
JBrowse link
G Bax BCL2-associated X protein increases expression
multiple interactions
EXP
ISO
Buthionine Sulfoximine results in increased expression of BAX protein
[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in decreased expression of BAX protein; Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in decreased expression of BAX protein]
CTD PMID:11341981 PMID:18552690 NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 decreases expression
multiple interactions
EXP
ISO
Buthionine Sulfoximine results in decreased expression of BCL2 mRNA; Buthionine Sulfoximine results in decreased expression of BCL2 protein
Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in decreased expression of BCL2 mRNA]
[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein]
Buthionine Sulfoximine promotes the reaction [cyanoginosin LR results in decreased expression of BCL2 protein]
CTD PMID:11341981 PMID:17989939 PMID:18552690 PMID:25410294 NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
JBrowse link
G Bmp1 bone morphogenetic protein 1 decreases expression EXP Buthionine Sulfoximine results in decreased expression of BMP1 mRNA CTD PMID:15878706 NCBI chr14:70,711,998...70,758,280
Ensembl chr14:70,711,998...70,757,674
JBrowse link
G Calr calreticulin increases expression ISO Buthionine Sulfoximine results in increased expression of CALR protein CTD PMID:23736079 NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
increases expression
EXP
ISO
4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP3 protein]; Glutathione inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP3 protein]; Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in increased expression of CASP3 mRNA]
[Buthionine Sulfoximine co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [monomethylarsonic acid co-treated with Buthionine Sulfoximine] results in increased activity of CASP3 protein; Buthionine Sulfoximine inhibits the reaction [Cacodylic Acid results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [Vitamin K 3 results in increased activity of CASP3 protein]
[O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate co-treated with Buthionine Sulfoximine] results in increased cleavage of CASP3 protein; Buthionine Sulfoximine promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased activity of CASP3 protein]
CTD PMID:10673743 PMID:15276415 PMID:15963344 PMID:16310883 PMID:17200146 More... NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
JBrowse link
G Casp4 caspase 4, apoptosis-related cysteine peptidase multiple interactions ISO Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased activity of CASP4 protein] CTD PMID:25341683 NCBI chr 9:5,308,816...5,336,791
Ensembl chr 9:5,308,828...5,336,783
JBrowse link
G Casp7 caspase 7 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate affects the cleavage of CASP7 protein] CTD PMID:20962031 NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
JBrowse link
G Casp8 caspase 8 multiple interactions ISO [Buthionine Sulfoximine co-treated with arsenic trioxide] results in increased cleavage of CASP8 protein; pyrazolanthrone inhibits the reaction [[Buthionine Sulfoximine co-treated with arsenic trioxide] results in increased cleavage of CASP8 protein] CTD PMID:17145888 NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
JBrowse link
G Casp9 caspase 9 multiple interactions
increases activity
EXP 4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP9 protein]; Glutathione inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP9 protein] CTD PMID:33309544 NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
JBrowse link
G Cat catalase decreases activity
multiple interactions
ISO
EXP
Buthionine Sulfoximine results in decreased activity of CAT protein
Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in decreased abundance of Glutathione]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]; CD36 mRNA promotes the reaction [CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]]
CTD PMID:21620807 PMID:21772021 PMID:26187465 NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
JBrowse link
G Ccl11 C-C motif chemokine ligand 11 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CCL11 mRNA CTD PMID:22407903 PMID:27421576 NCBI chr11:81,948,658...81,953,781
Ensembl chr11:81,948,649...81,953,781
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
increases expression
EXP
ISO
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CCL2 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CCL2 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CCL2 mRNA]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA]
CTD PMID:22407903 PMID:26177832 PMID:31294483 PMID:35123994 NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]] CTD PMID:11167962 NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of CCND1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of CCND1 protein] CTD PMID:17602960 NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
JBrowse link
G Cd163 CD163 antigen multiple interactions ISO [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA] CTD PMID:26177832 NCBI chr 6:124,281,596...124,307,488
Ensembl chr 6:124,281,615...124,307,486
JBrowse link
G Cd36 CD36 molecule increases expression
multiple interactions
EXP Buthionine Sulfoximine results in increased expression of CD36 protein
[pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CD36 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CD36 mRNA promotes the reaction [Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; CD36 mRNA promotes the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]; CD36 mRNA promotes the reaction [CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; PPARG mRNA promotes the reaction [Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]]; Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]
CTD PMID:26187465 PMID:27358406 PMID:28263783 NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799
JBrowse link
G Cd59b CD59b antigen increases mutagenesis ISO Buthionine Sulfoximine results in increased mutagenesis of CD59 gene CTD PMID:15033018 NCBI chr 2:103,900,127...103,920,619
Ensembl chr 2:103,896,142...103,921,534
JBrowse link
G Cd68 CD68 antigen multiple interactions ISO [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA] CTD PMID:26177832 NCBI chr11:69,555,039...69,556,996
Ensembl chr11:69,555,039...69,556,979
JBrowse link
G Cd86 CD86 antigen increases expression ISO Buthionine Sulfoximine results in increased expression of CD86 protein CTD PMID:20457211 NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443
JBrowse link
G Cdkn1a cyclin dependent kinase inhibitor 1A multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of CDKN1A protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1A protein] CTD PMID:17602960 NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
JBrowse link
G Cdkn1b cyclin dependent kinase inhibitor 1B multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of CDKN1B protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1B protein] CTD PMID:17602960 NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
JBrowse link
G Chek2 checkpoint kinase 2 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [potassium chromate(VI) results in increased expression of CHEK2 protein modified form] CTD PMID:25977998 NCBI chr 5:110,987,668...111,022,006
Ensembl chr 5:110,987,845...111,022,011
JBrowse link
G Cherp calcium homeostasis endoplasmic reticulum protein increases expression ISO Buthionine Sulfoximine results in increased expression of CHERP protein CTD PMID:23736079 NCBI chr 8:73,214,327...73,229,077
Ensembl chr 8:73,214,333...73,229,070
JBrowse link
G Col1a1 collagen, type I, alpha 1 multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of COL1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of COL1A1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 protein] CTD PMID:17602960 NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
JBrowse link
G Col1a2 collagen, type I, alpha 2 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [CYP2E1 protein results in increased expression of COL1A2 mRNA] CTD PMID:10498651 NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544
JBrowse link
G Col5a3 collagen, type V, alpha 3 decreases expression EXP Buthionine Sulfoximine results in decreased expression of COL5A3 mRNA CTD PMID:15878706 NCBI chr 9:20,681,353...20,726,363
Ensembl chr 9:20,681,346...20,726,363
JBrowse link
G Cox4i1 cytochrome c oxidase subunit 4I1 increases expression EXP Buthionine Sulfoximine results in increased expression of COX4I1 mRNA CTD PMID:15878706 NCBI chr 8:121,394,964...121,400,948
Ensembl chr 8:121,394,961...121,400,946
JBrowse link
G Cse1l chromosome segregation 1 like increases expression ISO Buthionine Sulfoximine results in increased expression of CSE1L protein CTD PMID:23736079 NCBI chr 2:166,747,961...166,788,309
Ensembl chr 2:166,747,960...166,788,309
JBrowse link
G Csf1 colony stimulating factor 1 (macrophage) increases expression
multiple interactions
EXP Buthionine Sulfoximine results in increased expression of CSF1 mRNA
Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CSF1 mRNA]
CTD PMID:35123994 NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions ISO [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA] CTD PMID:26177832 NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 decreases expression
increases expression
multiple interactions
EXP Buthionine Sulfoximine results in decreased expression of CXCL12 mRNA
Buthionine Sulfoximine results in increased expression of CXCL12 mRNA
Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CXCL12 mRNA]
CTD PMID:15878706 PMID:35123994 NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
JBrowse link
G Cxcl15 C-X-C motif chemokine ligand 15 increases secretion ISO Buthionine Sulfoximine results in increased secretion of CXCL8 protein CTD PMID:20457211 NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions EXP
ISO
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; Alprostadil inhibits the reaction [[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA]
CTD PMID:23986454 PMID:26177832 PMID:27421576 PMID:28263783 PMID:31294483 NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions EXP [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL1 mRNA; Buthionine Sulfoximine promotes the reaction [Tobacco Smoke Pollution results in increased secretion of and results in increased expression of CXCL1 protein] CTD PMID:26149495 PMID:31294483 NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression EXP Buthionine Sulfoximine results in decreased expression of CXCR4 mRNA CTD PMID:15878706 NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
increases activity
decreases activity
ISO
EXP
Buthionine Sulfoximine affects the reaction [Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Buthionine Sulfoximine inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]
Buthionine Sulfoximine inhibits the reaction [Methylcholanthrene results in increased activity of CYP1A1 protein]; Buthionine Sulfoximine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
[Buthionine Sulfoximine co-treated with 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide] inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; [Buthionine Sulfoximine co-treated with Cadmium Chloride] results in increased expression of CYP1A1 mRNA; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of CYP1A1 mRNA; Buthionine Sulfoximine inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; Buthionine Sulfoximine promotes the reaction [andrographolide affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [chromium trioxide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Mercury inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
Buthionine Sulfoximine results in increased activity of CYP1A1 protein
Buthionine Sulfoximine results in decreased activity of CYP1A1 protein
CTD PMID:9756946 PMID:16274885 PMID:16906435 PMID:18078826 PMID:19033395 More... NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 increases response to substance
multiple interactions
ISO CYP2E1 protein results in increased susceptibility to Buthionine Sulfoximine; CYP2E1 results in increased susceptibility to Buthionine Sulfoximine
Buthionine Sulfoximine promotes the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein]; Buthionine Sulfoximine promotes the reaction [CYP2E1 protein results in increased expression of COL1A2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin promotes the reaction [CYP2E1 protein results in increased susceptibility to Buthionine Sulfoximine]; Zinc Sulfate inhibits the reaction [CYP2E1 results in increased susceptibility to Buthionine Sulfoximine]
CTD PMID:10498651 PMID:12086689 PMID:12566070 PMID:22486562 NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
JBrowse link
G Dab1 disabled 1 decreases expression EXP Buthionine Sulfoximine results in decreased expression of DAB1 mRNA CTD PMID:15878706 NCBI chr 4:103,476,425...104,602,041
Ensembl chr 4:103,476,556...104,602,041
JBrowse link
G Dars1 aspartyl-tRNA synthetase 1 increases expression ISO Buthionine Sulfoximine results in increased expression of DARS1 protein CTD PMID:23736079 NCBI chr 1:128,291,444...128,345,153
Ensembl chr 1:128,291,444...128,345,105
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 mRNA]; Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of DDIT3 protein] CTD PMID:17171638 PMID:25341683 NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157
JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 decreases expression ISO Buthionine Sulfoximine results in decreased expression of DGAT2 mRNA CTD PMID:20482862 NCBI chr 7:98,802,870...98,831,920
Ensembl chr 7:98,802,865...98,831,926
JBrowse link
G Dio2 deiodinase, iodothyronine, type II multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Colforsin results in increased activity of DIO2 protein] CTD PMID:18420745 NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812
JBrowse link
G Dio3 deiodinase, iodothyronine type III increases activity ISO Buthionine Sulfoximine results in increased activity of DIO3 protein CTD PMID:18420745 NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531
JBrowse link
G Dld dihydrolipoamide dehydrogenase increases expression ISO Buthionine Sulfoximine results in increased expression of DLD protein CTD PMID:23736079 NCBI chr12:31,381,561...31,401,470
Ensembl chr12:31,381,276...31,401,452
JBrowse link
G Ech1 enoyl coenzyme A hydratase 1, peroxisomal increases expression EXP Buthionine Sulfoximine results in increased expression of ECH1 mRNA CTD PMID:15878706 NCBI chr 7:28,524,763...28,531,664
Ensembl chr 7:28,524,642...28,531,672
JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 increases expression EXP Buthionine Sulfoximine results in increased expression of EEF1A1 mRNA CTD PMID:15878706 NCBI chr 9:78,385,735...78,389,006
Ensembl chr 9:78,385,731...78,396,433
JBrowse link
G Eef1b2 eukaryotic translation elongation factor 1 beta 2 increases expression EXP Buthionine Sulfoximine results in increased expression of EEF1B2 mRNA CTD PMID:15878706 NCBI chr 1:63,215,990...63,219,645
Ensembl chr 1:63,215,984...63,219,645
JBrowse link
G Egr1 early growth response 1 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of EGR1 mRNA] CTD PMID:19010381 NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
JBrowse link
G Eif1a eukaryotic translation initiation factor 1A decreases expression EXP Buthionine Sulfoximine results in decreased expression of EIF1A mRNA CTD PMID:15878706 NCBI chr18:46,730,771...46,743,292
Ensembl chr18:46,730,768...46,749,523
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased phosphorylation of EIF2AK3 protein] CTD PMID:25341683 NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
JBrowse link
G Eif2b4 eukaryotic translation initiation factor 2B, subunit 4 delta decreases expression EXP Buthionine Sulfoximine results in decreased expression of EIF2B4 mRNA CTD PMID:15878706 NCBI chr 5:31,344,902...31,350,483
Ensembl chr 5:31,344,902...31,350,774
JBrowse link
G Eif3g eukaryotic translation initiation factor 3, subunit G decreases expression EXP Buthionine Sulfoximine results in decreased expression of EIF3G mRNA CTD PMID:15878706 NCBI chr 9:20,805,645...20,809,886
Ensembl chr 9:20,805,645...20,809,919
JBrowse link
G Esyt1 extended synaptotagmin-like protein 1 decreases expression EXP Buthionine Sulfoximine results in decreased expression of ESYT1 mRNA CTD PMID:15878706 NCBI chr10:128,346,117...128,361,728
Ensembl chr10:128,345,834...128,361,740
JBrowse link
G Etf1 eukaryotic translation termination factor 1 increases expression EXP Buthionine Sulfoximine results in increased expression of ETF1 mRNA CTD PMID:15707499 NCBI chr18:35,035,838...35,065,060
Ensembl chr18:35,035,838...35,065,060
JBrowse link
G Ezh1 enhancer of zeste 1 polycomb repressive complex 2 subunit decreases expression EXP Buthionine Sulfoximine results in decreased expression of EZH1 mRNA CTD PMID:15878706 NCBI chr11:101,081,941...101,117,268
Ensembl chr11:101,081,941...101,117,289
JBrowse link
G Fas Fas cell surface death receptor multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Copper deficiency results in increased expression of FAS mRNA] CTD PMID:9227460 NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
JBrowse link
G Fasl Fas ligand multiple interactions EXP [Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FASL mRNA CTD PMID:23986454 NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
JBrowse link
G Fkbp5 FK506 binding protein 5 increases expression ISO Buthionine Sulfoximine results in increased expression of FKBP5 protein CTD PMID:23736079 NCBI chr17:28,617,727...28,705,123
Ensembl chr17:28,618,068...28,736,501
JBrowse link
G Flt1 FMS-like tyrosine kinase 1 increases expression EXP Buthionine Sulfoximine results in increased expression of FLT1 mRNA CTD PMID:15878706 NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821
JBrowse link
G Fmo3 flavin containing monooxygenase 3 multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [FMO3 protein results in increased susceptibility to Thiourea] CTD PMID:12093470 NCBI chr 1:162,781,368...162,812,097
Ensembl chr 1:162,781,369...162,812,097
JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO [Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [manganese chloride results in increased expression of and results in increased secretion of FN1 protein] CTD PMID:19524604 NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
JBrowse link
G Fos FBJ osteosarcoma oncogene multiple interactions
increases expression
EXP
ISO
Buthionine Sulfoximine inhibits the reaction [Sodium Selenite results in increased expression of FOS mRNA]; Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]; Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA] CTD PMID:7743507 PMID:15520183 PMID:18449455 PMID:21825963 NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
JBrowse link
G Fosl1 fos-like antigen 1 multiple interactions EXP
ISO
Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of FOSL1 mRNA]
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of FOSL1 mRNA]
CTD PMID:15520183 PMID:19010381 NCBI chr19:5,497,726...5,505,966
Ensembl chr19:5,497,575...5,505,974
JBrowse link
G Foxp3 forkhead box P3 multiple interactions EXP
ISO
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FOXP3 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of FOXP3 mRNA
CTD PMID:23986454 PMID:26177832 NCBI chr  X:7,445,915...7,461,482
Ensembl chr  X:7,439,883...7,461,484
JBrowse link
G Fth1 ferritin heavy polypeptide 1 multiple interactions
increases expression
ISO
EXP
Buthionine Sulfoximine promotes the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of FTH1 mRNA]
Buthionine Sulfoximine results in increased expression of FTH1 mRNA
CTD PMID:15878706 PMID:16631525 NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462
JBrowse link
G G6pdx glucose-6-phosphate dehydrogenase X-linked increases expression ISO Buthionine Sulfoximine results in increased expression of G6PD mRNA CTD PMID:12717738 NCBI chr  X:73,453,089...73,472,486
Ensembl chr  X:73,453,089...73,472,800
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase multiple interactions
increases expression
ISO
EXP
[Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [1,2-naphthoquinone binds to GAPDH protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [1,2-naphthoquinone results in decreased activity of GAPDH protein]
Buthionine Sulfoximine results in increased expression of GAPDH mRNA
CTD PMID:15878706 PMID:21827172 NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430
JBrowse link
G Gata3 GATA binding protein 3 multiple interactions
decreases expression
EXP
ISO
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of GATA3 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of GATA3 mRNA
Buthionine Sulfoximine results in decreased expression of GATA3 mRNA
CTD PMID:22407903 PMID:23986454 PMID:26177832 PMID:27421576 NCBI chr 2:9,861,889...9,894,845
Ensembl chr 2:9,861,889...9,894,845
JBrowse link
G Gc vitamin D binding protein multiple interactions ISO [Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of GC mRNA CTD PMID:23288050 NCBI chr 5:89,565,370...89,605,757
Ensembl chr 5:89,565,381...89,605,757
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases activity
increases expression
multiple interactions
decreases activity
EXP
ISO
Buthionine Sulfoximine results in increased activity of GCLC protein
Buthionine Sulfoximine results in increased expression of GCLC mRNA
[Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GCLC protein; [Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GCLC protein; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [GCLC protein results in increased chemical synthesis of gamma-glutamylcysteine]; Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in increased expression of GCLC mRNA]
Buthionine Sulfoximine results in decreased activity of GCLC protein
Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLC protein] which results in increased abundance of Glutathione]; Buthionine Sulfoximine inhibits the reaction [GCLC results in decreased susceptibility to Cadmium Chloride]
[Buthionine Sulfoximine results in decreased activity of GCLC protein] inhibits the reaction [indenoindole results in increased abundance of Glutathione]; [Buthionine Sulfoximine results in decreased activity of GCLC protein] which results in decreased abundance of Glutathione; [Thiabendazole co-treated with Buthionine Sulfoximine] results in increased activity of GCLC protein; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [GCLC protein results in decreased susceptibility to naphthalene]; Buthionine Sulfoximine inhibits the reaction [Hypochlorous Acid results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [naphthalene results in increased activity of GCLC protein]; Buthionine Sulfoximine promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of GCLC mRNA]
CTD PMID:7955076 PMID:10900227 PMID:10915739 PMID:10978506 PMID:11019651 More... NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
JBrowse link
G Gclm glutamate-cysteine ligase, modifier subunit increases expression
multiple interactions
ISO Buthionine Sulfoximine results in increased expression of GCLM mRNA
[Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]
Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLM protein] which results in increased abundance of Glutathione]
CTD PMID:10978506 PMID:17724089 PMID:19010381 PMID:22864849 NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
JBrowse link
G Gdf15 growth differentiation factor 15 multiple interactions
increases expression
EXP Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of GDF15 mRNA] CTD PMID:35123994 NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106
JBrowse link
G Gdi2 GDP dissociation inhibitor 2 decreases expression EXP Buthionine Sulfoximine results in decreased expression of GDI2 mRNA CTD PMID:15878706 NCBI chr13:3,588,075...3,616,261
Ensembl chr13:3,588,063...3,617,871
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions ISO (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein CTD PMID:19850110 NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
JBrowse link
G Gmfb glia maturation factor, beta increases response to substance EXP GMFB protein results in increased susceptibility to Buthionine Sulfoximine CTD PMID:12791701 NCBI chr14:47,045,606...47,059,711
Ensembl chr14:47,045,606...47,059,699
JBrowse link
G Gpi1 glucose-6-phosphate isomerase 1 increases expression EXP Buthionine Sulfoximine results in increased expression of GPI1 mRNA CTD PMID:15878706 NCBI chr 7:33,900,752...33,929,761
Ensembl chr 7:33,900,755...33,929,761
JBrowse link
G Gpt glutamic pyruvic transaminase, soluble multiple interactions ISO
EXP
[allyl sulfide co-treated with dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate] inhibits the reaction [[Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]; [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein; [Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased expression of and results in increased activity of GPT protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein]; Ursodeoxycholic Acid inhibits the reaction [[Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of GPT protein; [Methimazole co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of GPT protein; Buthionine Sulfoximine promotes the reaction [[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein]; Tranylcypromine inhibits the reaction [[Methimazole co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]
CTD PMID:15950962 PMID:26177832 PMID:27421576 PMID:29679711 PMID:30853469 More... NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
JBrowse link
G Gpx1 glutathione peroxidase 1 affects activity
multiple interactions
EXP
ISO
Buthionine Sulfoximine affects the activity of GPX1 protein
Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of GPX1 mRNA]
Buthionine Sulfoximine promotes the reaction [Microcystins analog results in increased expression of GPX1 mRNA]
CTD PMID:15707499 PMID:24964298 PMID:25341683 NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
JBrowse link
G Gpx2 glutathione peroxidase 2 increases expression EXP Buthionine Sulfoximine results in increased expression of GPX2 mRNA CTD PMID:15878706 NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273
JBrowse link
G Gpx3 glutathione peroxidase 3 increases expression EXP Buthionine Sulfoximine results in increased expression of GPX3 mRNA CTD PMID:15878706 NCBI chr11:54,793,680...54,801,213
Ensembl chr11:54,793,279...54,801,203
JBrowse link
G Gpx4 glutathione peroxidase 4 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [Acrolein results in decreased expression of GPX4 mRNA] CTD PMID:33421550 NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273
JBrowse link
G Grb2 growth factor receptor bound protein 2 decreases expression EXP Buthionine Sulfoximine results in decreased expression of GRB2 mRNA CTD PMID:15878706 NCBI chr11:115,534,871...115,599,423
Ensembl chr11:115,534,871...115,599,423
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases phosphorylation EXP Buthionine Sulfoximine results in decreased phosphorylation of GSK3B protein CTD PMID:18552690 NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
JBrowse link
G Gsn gelsolin increases expression EXP Buthionine Sulfoximine results in increased expression of GSN mRNA CTD PMID:15878706 NCBI chr 2:35,146,371...35,197,914
Ensembl chr 2:35,146,392...35,197,904
JBrowse link
G Gsr glutathione reductase multiple interactions EXP
ISO
Buthionine Sulfoximine inhibits the reaction [schizandrin B results in increased activity of GSR protein]; Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]]
[Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GSR protein; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GSR protein; [cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased activity of GSR protein; Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in decreased expression of GSR mRNA]; Buthionine Sulfoximine inhibits the reaction [schizandrin B results in increased activity of GSR protein]; Buthionine Sulfoximine promotes the reaction [arsenic trioxide results in increased expression of GSR mRNA]
CTD PMID:12967637 PMID:16288907 PMID:17119269 PMID:21772021 PMID:24634002 More... NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
JBrowse link
G Gss glutathione synthetase decreases activity
increases expression
ISO Buthionine Sulfoximine results in decreased activity of GSS protein
Buthionine Sulfoximine results in increased expression of GSS mRNA
CTD PMID:10904027 PMID:10978506 NCBI chr 2:155,405,101...155,434,730
Ensembl chr 2:155,405,101...155,434,730
JBrowse link
G Gstm1 glutathione S-transferase, mu 1 increases expression EXP Buthionine Sulfoximine results in increased expression of GSTM1 mRNA CTD PMID:15878706 NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289
JBrowse link
G Gstm2 glutathione S-transferase, mu 2 increases expression EXP Buthionine Sulfoximine results in increased expression of GSTM2 mRNA CTD PMID:15878706 NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769
JBrowse link
G Gstp1 glutathione S-transferase, pi 1 multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [GSTP1 results in decreased susceptibility to Benzo(a)pyrene]
Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in increased expression of GSTP1 mRNA]
CTD PMID:19330882 PMID:24964298 NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
JBrowse link
G Hadh hydroxyacyl-Coenzyme A dehydrogenase increases expression EXP Buthionine Sulfoximine results in increased expression of HADH mRNA CTD PMID:15878706 NCBI chr 3:131,027,068...131,065,750
Ensembl chr 3:131,027,068...131,065,750
JBrowse link
G Hbs1l Hbs1-like (S. cerevisiae) decreases expression EXP Buthionine Sulfoximine results in decreased expression of HBS1L mRNA CTD PMID:15878706 NCBI chr10:21,171,876...21,244,788
Ensembl chr10:21,171,878...21,244,797
JBrowse link
G Hdgf heparin binding growth factor increases expression EXP Buthionine Sulfoximine results in increased expression of HDGF mRNA CTD PMID:15878706 NCBI chr 3:87,813,844...87,823,439
Ensembl chr 3:87,813,628...87,823,439
JBrowse link
G Hgf hepatocyte growth factor increases expression ISO Buthionine Sulfoximine results in increased expression of HGF protein CTD PMID:9763232 NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150
JBrowse link
G Hif1a hypoxia inducible factor 1, alpha subunit multiple interactions
increases activity
ISO Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of HIF1A protein]
Buthionine Sulfoximine results in increased activity of HIF1A protein
CTD PMID:11641398 PMID:11841787 PMID:17658243 NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions EXP
ISO
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of HMGB1 protein
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein]
CTD PMID:23986454 PMID:26177832 NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299
JBrowse link
G Hmgb2 high mobility group box 2 increases expression EXP Buthionine Sulfoximine results in increased expression of HMGB2 mRNA CTD PMID:15707499 NCBI chr 8:57,964,877...57,969,033
Ensembl chr 8:57,964,941...57,969,033
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
ISO
EXP
1-aminobenzotriazole inhibits the reaction [[Acetaminophen co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Butylated Hydroxyanisole co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Diclofenac co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Ticlopidine co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]; [2-tert-butylhydroquinone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine co-treated with Ascorbic Acid] promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA]; [Buthionine Sulfoximine co-treated with Dehydroascorbic Acid] promotes the reaction [cupric oxide results in increased expression of HMOX1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA; [monocrystalline iron oxide nanoparticle co-treated with Buthionine Sulfoximine co-treated with Dehydroascorbic Acid] results in increased expression of HMOX1 mRNA; [monocrystalline iron oxide nanoparticle co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine promotes the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Acetaminophen results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Butylated Hydroxyanisole results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]; Buthionine Sulfoximine promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [cupric oxide results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Potassium Dichromate results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Ticlopidine results in increased expression of HMOX1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]
Buthionine Sulfoximine results in increased expression of HMOX1 mRNA
[6-formylindolo(3,2-b)carbazole co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[chromium trioxide co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[sodium arsenite co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased expression of HMOX1 protein]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of HMOX1 mRNA]; Diclofenac promotes the reaction [Buthionine Sulfoximine results in increased expression of HMOX1 protein]
Buthionine Sulfoximine results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine results in increased expression of HMOX1 protein
CTD PMID:7626009 PMID:9152014 PMID:11841787 PMID:12763371 PMID:16274885 More... NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
JBrowse link
G Hmox2 heme oxygenase 2 affects response to substance EXP HMOX2 affects the susceptibility to Buthionine Sulfoximine CTD PMID:16181104 NCBI chr16:4,544,225...4,584,606
Ensembl chr16:4,544,225...4,584,606
JBrowse link
G Hnrnpm heterogeneous nuclear ribonucleoprotein M increases expression ISO Buthionine Sulfoximine results in increased expression of HNRNPM protein CTD PMID:23736079 NCBI chr17:33,865,207...33,904,432
Ensembl chr17:33,865,207...33,905,834
JBrowse link
G Hsp90aa1 heat shock protein 90, alpha (cytosolic), class A member 1 increases expression ISO Buthionine Sulfoximine results in increased expression of HSP90AA1 protein CTD PMID:23736079 NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
JBrowse link
G Hsp90ab1 heat shock protein 90 alpha (cytosolic), class B member 1 increases expression EXP Buthionine Sulfoximine results in increased expression of HSP90AB1 mRNA CTD PMID:15707499 NCBI chr17:45,878,704...45,884,187
Ensembl chr17:45,878,701...45,884,197
JBrowse link
G Hspa4 heat shock protein 4 increases expression ISO Buthionine Sulfoximine results in increased expression of HSPA4 protein CTD PMID:23736079 NCBI chr11:53,150,641...53,191,306
Ensembl chr11:53,150,641...53,191,284
JBrowse link
G Hspa5 heat shock protein 5 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of HSPA5 protein] CTD PMID:25341683 NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
JBrowse link
G Hspa8 heat shock protein 8 increases expression EXP
ISO
Buthionine Sulfoximine results in increased expression of HSPA8 mRNA CTD PMID:7626009 PMID:15707499 NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
increases expression
ISO
EXP
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]
[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of ICAM1 mRNA
CTD PMID:11164475 PMID:20116392 PMID:20351055 PMID:29154782 NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [INS1 protein results in decreased expression of IGFBP1 mRNA] CTD PMID:17213664 NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546
JBrowse link
G Il10 interleukin 10 multiple interactions EXP
ISO
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]; Buthionine Sulfoximine promotes the reaction [methyldithiocarbamate promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA]
CTD PMID:19339665 PMID:26177832 NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
JBrowse link
G Il12b interleukin 12b multiple interactions EXP Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein]; Buthionine Sulfoximine inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]] CTD PMID:12688424 PMID:19339665 NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860
JBrowse link
G Il17a interleukin 17A multiple interactions EXP [Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL17A protein CTD PMID:23986454 NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720
JBrowse link
G Il1a interleukin 1 alpha multiple interactions EXP [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of IL1A mRNA; LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of IL1A mRNA] CTD PMID:29154782 NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases secretion
ISO
EXP
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL1B mRNA; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of IL1B protein]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL1B mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL1B protein; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Buthionine Sulfoximine promotes the reaction [hydroxyethyl methacrylate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; Buthionine Sulfoximine promotes the reaction [Tobacco Smoke Pollution results in increased secretion of and results in increased expression of IL1B protein]
CTD PMID:11970852 PMID:12433058 PMID:23986454 PMID:26149495 PMID:26177832 More... NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
JBrowse link
G Il23a interleukin 23, alpha subunit p19 multiple interactions EXP [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL23A mRNA CTD PMID:23986454 NCBI chr10:128,132,009...128,133,953
Ensembl chr10:128,132,008...128,134,621
JBrowse link
G Il4 interleukin 4 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of IL4 protein; Buthionine Sulfoximine promotes the reaction [Methimazole results in increased expression of IL4 protein] CTD PMID:22407903 PMID:27421576 NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
JBrowse link
G Il6 interleukin 6 increases secretion
multiple interactions
ISO
EXP
Buthionine Sulfoximine results in increased secretion of IL6 protein
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of IL6 protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of IL6 protein]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA]
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Buthionine Sulfoximine inhibits the reaction [manganese chloride promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; Buthionine Sulfoximine inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]
CTD PMID:11970852 PMID:12433058 PMID:15601679 PMID:19339665 PMID:23986454 More... NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
JBrowse link
G Ins1 insulin I multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [INS1 protein results in decreased expression of IGFBP1 mRNA] CTD PMID:17213664 NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
JBrowse link
G Jak1 Janus kinase 1 increases expression EXP Buthionine Sulfoximine results in increased expression of JAK1 mRNA CTD PMID:15878706 NCBI chr 4:101,009,171...101,122,493
Ensembl chr 4:101,009,564...101,122,479
JBrowse link
G Jak2 Janus kinase 2 decreases expression EXP Buthionine Sulfoximine results in decreased expression of JAK2 mRNA CTD PMID:15878706 NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480
JBrowse link
G Jun jun proto-oncogene multiple interactions
decreases activity
increases expression
EXP
ISO
Buthionine Sulfoximine inhibits the reaction [Sodium Selenite results in increased expression of JUN mRNA]; Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of JUN mRNA]; Buthionine Sulfoximine promotes the reaction [Trioxsalen analog results in decreased activity of JUN protein]; Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA]
Buthionine Sulfoximine results in decreased activity of JUN protein
Buthionine Sulfoximine inhibits the reaction [Cadmium Chloride results in increased expression of JUN mRNA]
CTD PMID:7626009 PMID:7743507 PMID:11341981 PMID:11841787 PMID:11849044 More... NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
JBrowse link
G Junb jun B proto-oncogene multiple interactions EXP Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of JUNB mRNA] CTD PMID:15520183 NCBI chr 8:85,703,538...85,705,377
Ensembl chr 8:85,701,113...85,705,347
JBrowse link
G Kcna4 potassium voltage-gated channel, shaker-related subfamily, member 4 multiple interactions ISO [Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCNA4 protein CTD PMID:16288907 NCBI chr 2:107,120,934...107,157,149
Ensembl chr 2:107,120,984...107,128,847
JBrowse link
G Kcnd2 potassium voltage-gated channel, Shal-related family, member 2 multiple interactions ISO [Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 mRNA; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 protein CTD PMID:16288907 NCBI chr 6:21,212,101...21,729,804
Ensembl chr 6:21,215,502...21,729,804
JBrowse link
G Keap1 kelch-like ECH-associated protein 1 multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Acrolein]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in increased abundance of Glutathione] CTD PMID:19608619 NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
JBrowse link
G Klf4 Kruppel-like transcription factor 4 (gut) multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [KLF4 results in decreased susceptibility to Cisplatin] CTD PMID:21833590 NCBI chr 4:55,527,137...55,536,984
Ensembl chr 4:55,527,143...55,532,466
JBrowse link
G Klf6 Kruppel-like transcription factor 6 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein] CTD PMID:22486562 NCBI chr13:5,911,488...5,920,392
Ensembl chr13:5,911,481...5,920,393
JBrowse link
G Kpnb1 karyopherin subunit beta 1 increases expression ISO Buthionine Sulfoximine results in increased expression of KPNB1 protein CTD PMID:23736079 NCBI chr11:97,050,536...97,078,718
Ensembl chr11:97,050,540...97,078,707
JBrowse link
G Lcn2 lipocalin 2 increases expression
multiple interactions
ISO
EXP
Buthionine Sulfoximine results in increased expression of LCN2 mRNA
Diclofenac promotes the reaction [Buthionine Sulfoximine results in increased expression of LCN2 mRNA]
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of LCN2 mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of LCN2 mRNA; [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of LCN2 mRNA; LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of LCN2 mRNA]
CTD PMID:23939143 PMID:29154782 PMID:29679711 PMID:30853469 NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264
JBrowse link
G Lef1 lymphoid enhancer binding factor 1 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of LEF1 protein CTD PMID:27421576 NCBI chr 3:130,903,972...131,018,006
Ensembl chr 3:130,904,120...131,018,005
JBrowse link
G Lrpprc leucine-rich PPR-motif containing increases expression ISO Buthionine Sulfoximine results in increased expression of LRPPRC protein CTD PMID:23736079 NCBI chr17:85,012,675...85,098,214
Ensembl chr17:85,012,675...85,098,217
JBrowse link
G Ly6g lymphocyte antigen 6 family member G multiple interactions EXP LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of IL1A mRNA]; LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of LCN2 mRNA] CTD PMID:29154782 NCBI chr15:75,027,110...75,030,977
Ensembl chr15:75,027,089...75,030,975
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions
increases expression
ISO Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein]; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in increased expression of MAP1LC3B protein]
Buthionine Sulfoximine results in increased expression of MAP1LC3B protein; Buthionine Sulfoximine results in increased expression of MAP1LC3B protein modified form
CTD PMID:34580807 NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 multiple interactions ISO [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [chromium hexavalent ion results in increased activity of MAPK1 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein]
[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased phosphorylation of MAPK1 protein; [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK1 protein; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK1 protein; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK1 protein]
CTD PMID:8616849 PMID:17191120 PMID:21971136 PMID:24401988 PMID:26177832 More... NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
JBrowse link
G Mapk11 mitogen-activated protein kinase 11 decreases expression
multiple interactions
EXP Buthionine Sulfoximine results in decreased expression of MAPK11 mRNA
Sodium Selenite inhibits the reaction [Buthionine Sulfoximine results in decreased expression of MAPK11 mRNA]
CTD PMID:17989939 NCBI chr15:89,026,685...89,033,809
Ensembl chr15:89,026,689...89,033,831
JBrowse link
G Mapk14 mitogen-activated protein kinase 14 increases phosphorylation ISO Buthionine Sulfoximine results in increased phosphorylation of MAPK14 protein CTD PMID:17191120 NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions ISO [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [chromium hexavalent ion results in increased activity of MAPK3 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein]
[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased phosphorylation of MAPK3 protein; [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK3 protein; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK3 protein; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK3 protein]
CTD PMID:8616849 PMID:17191120 PMID:21971136 PMID:24401988 PMID:26177832 More... NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO [antimony trioxide co-treated with Buthionine Sulfoximine] results in decreased expression of MAPK8 protein; Buthionine Sulfoximine promotes the reaction [antimony trioxide results in increased activity of MAPK8 protein]; Buthionine Sulfoximine promotes the reaction [arsenic trioxide results in increased activity of MAPK8 protein] CTD PMID:14701702 PMID:16112521 NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 decreases phosphorylation ISO Buthionine Sulfoximine results in decreased phosphorylation of MAPK9 protein CTD PMID:17191120 NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
JBrowse link
G Mapt microtubule-associated protein tau multiple interactions ISO (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein CTD PMID:19850110 NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916
JBrowse link
G Mars1 methionine-tRNA synthetase 1 increases expression ISO Buthionine Sulfoximine results in increased expression of MARS1 protein CTD PMID:23736079 NCBI chr10:127,132,090...127,147,655
Ensembl chr10:127,132,090...127,147,655
JBrowse link
G Mb myoglobin multiple interactions EXP [Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased secretion of MB protein CTD PMID:29679711 NCBI chr15:76,899,687...76,934,868
Ensembl chr15:76,899,687...76,934,870
JBrowse link
G Mef2a myocyte enhancer factor 2A increases expression EXP Buthionine Sulfoximine results in increased expression of MEF2A mRNA CTD PMID:15878706 NCBI chr 7:66,880,911...67,026,435
Ensembl chr 7:66,880,911...67,022,606
JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase multiple interactions
decreases activity
ISO Buthionine Sulfoximine inhibits the reaction [MGMT protein results in increased susceptibility to Mitomycin]
Buthionine Sulfoximine results in decreased activity of MGMT protein
CTD PMID:16039682 PMID:16950796 NCBI chr 7:136,496,315...136,732,001
Ensembl chr 7:136,496,343...136,731,995
JBrowse link
G Mir101b microRNA 101b multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR101B mRNA CTD PMID:27421576 NCBI chr19:29,112,679...29,112,775
Ensembl chr19:29,112,679...29,112,775
JBrowse link
G Mir106b microRNA 106b multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR106B mRNA CTD PMID:27421576 NCBI chr 5:138,163,999...138,164,080
Ensembl chr 5:138,163,999...138,164,080
JBrowse link
G Mir127 microRNA 127 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR127 mRNA CTD PMID:27421576 NCBI chr12:109,559,280...109,559,349
Ensembl chr12:109,559,280...109,559,349
JBrowse link
G Mir133b microRNA 133b multiple interactions EXP [Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR133B mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR133B mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR133B mRNA CTD PMID:28263783 PMID:29679711 PMID:30853469 NCBI chr 1:20,752,993...20,753,111
Ensembl chr 1:20,752,993...20,753,111
JBrowse link
G Mir136 microRNA 136 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR136 mRNA CTD PMID:27421576 NCBI chr12:109,561,761...109,561,822
Ensembl chr12:109,561,761...109,561,822
JBrowse link
G Mir137 microRNA 137 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR137 mRNA CTD PMID:27421576 NCBI chr 3:118,227,506...118,227,578
Ensembl chr 3:118,227,506...118,227,578
JBrowse link
G Mir138-1 microRNA 138-1 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR138-1 mRNA CTD PMID:27421576 NCBI chr 9:122,511,941...122,512,039
Ensembl chr 9:122,511,941...122,512,039
JBrowse link
G Mir141 microRNA 141 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR141 mRNA CTD PMID:27421576 NCBI chr 6:124,694,877...124,694,948
Ensembl chr 6:124,694,877...124,694,948
JBrowse link
G Mir148b microRNA 148b multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR148B mRNA CTD PMID:27421576 NCBI chr15:103,193,552...103,193,648
Ensembl chr15:103,193,552...103,193,648
JBrowse link
G Mir149 microRNA 149 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR149 mRNA CTD PMID:27421576 NCBI chr 1:92,778,100...92,778,165
Ensembl chr 1:92,778,100...92,778,165
JBrowse link
G Mir151 microRNA 151 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR151 mRNA CTD PMID:27421576 NCBI chr15:73,126,664...73,126,731
Ensembl chr15:73,126,664...73,126,731
JBrowse link
G Mir16-1 microRNA 16-1 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR16-1 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR16-1 mRNA CTD PMID:27421576 NCBI chr14:61,869,329...61,869,421
Ensembl chr14:61,869,329...61,869,421
JBrowse link
G Mir182 microRNA 182 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR182 mRNA CTD PMID:27421576 NCBI chr 6:30,165,917...30,165,991
Ensembl chr 6:30,165,917...30,165,991
JBrowse link
G Mir1839 microRNA 1839 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR1839 mRNA CTD PMID:27421576 NCBI chr 7:81,179,664...81,179,736
Ensembl chr 7:81,179,664...81,179,736
JBrowse link
G Mir184 microRNA 184 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR184 mRNA CTD PMID:27421576 NCBI chr 9:89,684,313...89,684,381
Ensembl chr 9:89,684,313...89,684,381
JBrowse link
G Mir187 microRNA 187 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR187 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR187 mRNA CTD PMID:27421576 NCBI chr18:24,562,167...24,562,227
Ensembl chr18:24,562,167...24,562,227
JBrowse link
G Mir188 microRNA 188 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR188 mRNA CTD PMID:27421576 NCBI chr  X:7,114,228...7,114,295
Ensembl chr  X:7,114,228...7,114,295
JBrowse link
G Mir1897 microRNA 1897 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR1897 mRNA CTD PMID:27421576 NCBI chr 3:34,692,613...34,692,691
Ensembl chr 3:34,692,613...34,692,691
JBrowse link
G Mir1903 microRNA 1903 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR1903 mRNA CTD PMID:27421576 NCBI chr 8:129,085,722...129,085,801
Ensembl chr 8:129,085,722...129,085,801
JBrowse link
G Mir190a microRNA 190a multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR190A mRNA CTD PMID:27421576 NCBI chr 9:67,143,942...67,144,008
Ensembl chr 9:67,143,942...67,144,008
JBrowse link
G Mir1928 microRNA 1928 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR1928 mRNA CTD PMID:27421576 NCBI chr 1:74,245,713...74,245,779
Ensembl chr 1:74,245,713...74,245,779
JBrowse link
G Mir1948 microRNA 1948 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR1948 mRNA CTD PMID:27421576 NCBI chr18:12,847,868...12,847,952
Ensembl chr18:12,847,868...12,847,952
JBrowse link
G Mir19a microRNA 19a multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR19A mRNA CTD PMID:27421576 NCBI chr14:115,281,432...115,281,513
Ensembl chr14:115,281,432...115,281,513
JBrowse link
G Mir200a microRNA 200a multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR200A mRNA CTD PMID:27421576 NCBI chr 4:156,139,353...156,139,442
Ensembl chr 4:156,139,353...156,139,442
JBrowse link
G Mir206 microRNA 206 multiple interactions EXP [Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR206 mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR206 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR206 mRNA CTD PMID:28263783 PMID:29679711 PMID:30853469 NCBI chr 1:20,749,234...20,749,306
Ensembl chr 1:20,749,234...20,749,306
JBrowse link
G Mir20b microRNA 20b multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR20B mRNA CTD PMID:27421576 NCBI chr  X:51,830,990...51,831,069
Ensembl chr  X:51,830,990...51,831,069
JBrowse link
G Mir210 microRNA 210 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR210 mRNA CTD PMID:27421576 NCBI chr 7:140,801,297...140,801,406
Ensembl chr 7:140,801,297...140,801,406
JBrowse link
G Mir211 microRNA 211 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR211 mRNA CTD PMID:27421576 NCBI chr 7:63,855,554...63,855,659
Ensembl chr 7:63,855,554...63,855,659
JBrowse link
G Mir224 microRNA 224 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR224 mRNA CTD PMID:27421576 NCBI chr  X:71,304,637...71,304,718
Ensembl chr  X:71,304,637...71,304,718
JBrowse link
G Mir292 microRNA 292 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR292 mRNA CTD PMID:27421576 NCBI chr 7:3,267,863...3,267,944
Ensembl chr 7:3,267,863...3,267,944
JBrowse link
G Mir295 microRNA 295 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR295 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR295 mRNA CTD PMID:27421576 NCBI chr 7:3,269,447...3,269,515
Ensembl chr 7:3,269,447...3,269,515
JBrowse link
G Mir29b-1 microRNA 29b-1 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR29B-1 mRNA CTD PMID:27421576 NCBI chr 6:31,039,958...31,040,028
Ensembl chr 6:31,039,958...31,040,028
JBrowse link
G Mir29c microRNA 29c multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR29C mRNA CTD PMID:27421576 NCBI chr 1:194,719,855...194,719,942
Ensembl chr 1:194,719,855...194,719,942
JBrowse link
G Mir322 microRNA 322 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR322 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR322 mRNA CTD PMID:27421576 NCBI chr  X:52,143,132...52,143,226
Ensembl chr  X:52,143,132...52,143,226
JBrowse link
G Mir324 microRNA 324 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR324 mRNA CTD PMID:27421576 NCBI chr11:69,902,869...69,902,957
Ensembl chr11:69,902,869...69,902,957
JBrowse link
G Mir328 microRNA 328 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR328 mRNA CTD PMID:27421576 NCBI chr 8:106,034,996...106,035,092
Ensembl chr 8:106,034,996...106,035,092
JBrowse link
G Mir337 microRNA 337 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR337 mRNA CTD PMID:27421576 NCBI chr12:109,552,223...109,552,319
Ensembl chr12:109,552,223...109,552,319
JBrowse link
G Mir338 microRNA 338 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR338 mRNA CTD PMID:27421576 NCBI chr11:119,905,591...119,905,688
Ensembl chr11:119,905,591...119,905,688
JBrowse link
G Mir339 microRNA 339 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR339 mRNA CTD PMID:27421576 NCBI chr 5:139,355,405...139,355,500
Ensembl chr 5:139,355,405...139,355,500
JBrowse link
G Mir34b microRNA 34b multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR34B mRNA CTD PMID:27421576 NCBI chr 9:51,014,862...51,014,945
Ensembl chr 9:51,014,862...51,014,945
JBrowse link
G Mir350 microRNA 350 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR350 mRNA CTD PMID:27421576 NCBI chr 1:176,599,891...176,599,989
Ensembl chr 1:176,599,891...176,599,989
JBrowse link
G Mir361 microRNA 361 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR361 mRNA CTD PMID:27421576 NCBI chr  X:111,984,521...111,984,590
Ensembl chr  X:111,984,521...111,984,590
JBrowse link
G Mir362 microRNA 362 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR362 mRNA CTD PMID:27421576 NCBI chr  X:7,108,221...7,108,285
Ensembl chr  X:7,108,221...7,108,285
JBrowse link
G Mir375 microRNA 375 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR375 mRNA CTD PMID:27421576 NCBI chr 1:74,939,817...74,939,880
Ensembl chr 1:74,939,817...74,939,880
JBrowse link
G Mir410 microRNA 410 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR410 mRNA CTD PMID:27421576 NCBI chr12:109,710,149...109,710,229
Ensembl chr12:109,710,149...109,710,229
JBrowse link
G Mir449a microRNA 449a multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR449A mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR449A mRNA CTD PMID:27421576 NCBI chr13:113,174,068...113,174,158
Ensembl chr13:113,174,068...113,174,158
JBrowse link
G Mir450-1 microRNA 450-1 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR450A1 mRNA CTD PMID:27421576 NCBI chr  X:52,137,031...52,137,121
Ensembl chr  X:52,137,031...52,137,121
JBrowse link
G Mir455 microRNA 455 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR455 mRNA CTD PMID:27421576 NCBI chr 4:63,175,088...63,175,169
Ensembl chr 4:63,175,088...63,175,169
JBrowse link
G Mir511 microRNA 511 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR511 mRNA CTD PMID:27421576 NCBI chr 2:14,265,814...14,265,892
Ensembl chr 2:14,265,814...14,265,892
JBrowse link
G Mir669n microRNA 669n multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR669N mRNA CTD PMID:27421576 NCBI chr 3:115,773,551...115,773,604
Ensembl chr 3:115,773,551...115,773,604
JBrowse link
G Mir671 microRNA 671 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR671 mRNA CTD PMID:27421576 NCBI chr 5:24,797,112...24,797,209
Ensembl chr 5:24,797,112...24,797,209
JBrowse link
G Mir672 microRNA 672 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR672 mRNA CTD PMID:27421576 NCBI chr  X:103,159,781...103,159,880
Ensembl chr  X:103,159,781...103,159,880
JBrowse link
G Mir674 microRNA 674 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR674 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR674 mRNA CTD PMID:27421576 NCBI chr 2:117,015,608...117,015,707
Ensembl chr 2:117,015,608...117,015,707
JBrowse link
G Mir706 microRNA 706 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR706 mRNA CTD PMID:27421576 NCBI chr 6:120,011,189...120,011,272
Ensembl chr 6:120,011,189...120,011,272
JBrowse link
G Mir741 microRNA 741 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR741 mRNA CTD PMID:27421576 NCBI chr  X:65,840,411...65,840,481
Ensembl chr  X:65,840,411...65,840,481
JBrowse link
G Mir744 microRNA 744 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR744 mRNA CTD PMID:27421576 NCBI chr11:65,625,559...65,625,658
Ensembl chr11:65,625,559...65,625,658
JBrowse link
G Mir872 microRNA 872 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR872 mRNA CTD PMID:27421576 NCBI chr 4:94,553,394...94,553,474
Ensembl chr 4:94,553,394...94,553,474
JBrowse link
G Mir881 microRNA 881 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR881 mRNA CTD PMID:27421576 NCBI chr  X:65,845,550...65,845,627
Ensembl chr  X:65,845,550...65,845,627
JBrowse link
G Mir99a microRNA 99a multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR99A mRNA CTD PMID:27421576 NCBI chr16:77,395,824...77,395,888
Ensembl chr16:77,395,824...77,395,888
JBrowse link
G Mmp1b matrix metallopeptidase 1b (interstitial collagenase) multiple interactions ISO [Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA] CTD PMID:10464329 NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of MPO protein CTD PMID:26177832 NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
JBrowse link
G Mrps7 mitchondrial ribosomal protein S7 increases expression EXP Buthionine Sulfoximine results in increased expression of MRPS7 mRNA CTD PMID:15878706 NCBI chr11:115,494,966...115,498,862
Ensembl chr11:115,494,751...115,498,862
JBrowse link
G Mt1 metallothionein 1 multiple interactions
increases activity
EXP Buthionine Sulfoximine promotes the reaction [Copper results in increased activity of MT1 promoter]; Buthionine Sulfoximine promotes the reaction [Paraquat results in increased expression of MT1 mRNA]; Dactinomycin inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Paraquat results in increased expression of MT1 mRNA]]
Buthionine Sulfoximine results in increased activity of MT1 promoter
CTD PMID:8966720 PMID:14576086 NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955
JBrowse link
G Mt2 metallothionein 2 multiple interactions EXP [Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of MT2 mRNA CTD PMID:32741899 NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196
JBrowse link
G Mtf1 metal response element binding transcription factor 1 multiple interactions
decreases response to substance
EXP MTF1 results in decreased susceptibility to [Buthionine Sulfoximine co-treated with cadmium sulfate]
MTF1 results in decreased susceptibility to Buthionine Sulfoximine
CTD PMID:16221973 NCBI chr 4:124,696,342...124,743,593
Ensembl chr 4:124,695,897...124,743,593
JBrowse link
G Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Buthionine Sulfoximine inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]; Glutathione inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; mecobalamin inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]] CTD PMID:26989453 NCBI chr13:12,196,217...12,273,090
Ensembl chr13:12,197,598...12,272,999
JBrowse link
G Nars1 asparaginyl-tRNA synthetase 1 increases expression ISO Buthionine Sulfoximine results in increased expression of NARS1 protein CTD PMID:23736079 NCBI chr18:64,632,726...64,649,586
Ensembl chr18:64,632,718...64,649,723
JBrowse link
G Ndn necdin, MAGE family member increases expression EXP Buthionine Sulfoximine results in increased expression of NDN mRNA CTD PMID:15878706 NCBI chr 7:61,998,025...61,999,676
Ensembl chr 7:61,996,317...62,000,010
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 increases expression EXP Buthionine Sulfoximine results in increased expression of NDUFA13 mRNA CTD PMID:15878706 NCBI chr 8:70,346,813...70,355,208
Ensembl chr 8:70,346,830...70,355,208
JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 multiple interactions
increases expression
affects expression
ISO
EXP
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which affects the localization of NFE2L2 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which affects the localization of NFE2L2 protein; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Acrolein]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in increased abundance of Glutathione]; Buthionine Sulfoximine promotes the reaction [1,2-dihydroxynaphthalene analog results in increased activity of NFE2L2 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased phosphorylation of NFE2L2 protein]
[6-formylindolo(3,2-b)carbazole co-treated with Buthionine Sulfoximine] results in increased expression of NFE2L2 mRNA; Buthionine Sulfoximine affects the localization of and results in increased activity of NFE2L2 protein; Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Acrolein]; Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [Dextromethorphan results in increased activity of NFE2L2 protein]; Buthionine Sulfoximine inhibits the reaction [Hypochlorous Acid results in increased expression of NFE2L2 mRNA]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Acrolein]]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Chlorambucil]]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to cumene hydroperoxide]]
Buthionine Sulfoximine results in increased expression of NFE2L2 mRNA
Buthionine Sulfoximine affects the expression of NFE2L2 protein
Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of and affects the localization of NFE2L2 protein]; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of NFE2L2 mRNA]; Buthionine Sulfoximine promotes the reaction [arsenic trioxide results in increased expression of and affects the localization of NFE2L2 protein]
CTD PMID:17980396 PMID:18785192 PMID:19303893 PMID:19608619 PMID:20932822 More... NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
JBrowse link
G Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased activity of [NFKB1 protein binds to RELA protein]] CTD PMID:11970852 PMID:12433058 NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
JBrowse link
G Nfkbia nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha multiple interactions
increases expression
ISO
EXP
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]
Buthionine Sulfoximine results in increased expression of NFKBIA mRNA
NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of NFKBIA mRNA]
CTD PMID:11970852 PMID:12433058 PMID:23472850 NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
JBrowse link
G Ngf nerve growth factor multiple interactions
increases expression
affects response to substance
EXP Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of NGF mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of NFKBIA mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of TXN1 mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein]
NGF protein affects the susceptibility to Buthionine Sulfoximine
CTD PMID:23472850 NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions EXP
ISO
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of NLRP3 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of NLRP3 mRNA
CTD PMID:23986454 PMID:26177832 NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
JBrowse link
G Nos2 nitric oxide synthase 2, inducible multiple interactions
increases expression
EXP
ISO
Buthionine Sulfoximine promotes the reaction [Trioxsalen analog results in decreased expression of NOS2 mRNA]
[Carmustine co-treated with Buthionine Sulfoximine] inhibits the reaction [TNF protein results in increased expression of NOS2 protein]; Buthionine Sulfoximine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]; Buthionine Sulfoximine promotes the reaction [Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]]; Buthionine Sulfoximine promotes the reaction [Potassium Cyanide results in increased expression of NOS2 protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Buthionine Sulfoximine]
Buthionine Sulfoximine results in increased expression of NOS2 mRNA
[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA]
CTD PMID:7532384 PMID:9826428 PMID:16259964 PMID:16933320 PMID:23939143 NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
JBrowse link
G Npc1 NPC intracellular cholesterol transporter 1 decreases expression EXP Buthionine Sulfoximine results in decreased expression of NPC1 mRNA CTD PMID:15878706 NCBI chr18:12,322,751...12,369,851
Ensembl chr18:12,322,749...12,369,457
JBrowse link
G Nqo1 NAD(P)H dehydrogenase, quinone 1 increases activity
multiple interactions
increases expression
ISO
EXP
Buthionine Sulfoximine results in increased activity of NQO1 protein
[Buthionine Sulfoximine co-treated with Endosulfan] results in increased expression of NQO1 mRNA; Buthionine Sulfoximine promotes the reaction [Methylcholanthrene results in increased activity of NQO1 protein]; Methylcholanthrene promotes the reaction [Buthionine Sulfoximine results in increased activity of NQO1 protein]
[Buthionine Sulfoximine co-treated with chromium trioxide] results in increased activity of NQO1 protein; [Buthionine Sulfoximine co-treated with chromium trioxide] results in increased expression of NQO1 mRNA; [Tetrachlorodibenzodioxin co-treated with chromium trioxide co-treated with Buthionine Sulfoximine] results in increased expression of NQO1 mRNA; Buthionine Sulfoximine inhibits the reaction [chromium trioxide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]]; Buthionine Sulfoximine inhibits the reaction [sodium arsenite promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]]; Buthionine Sulfoximine inhibits the reaction [sodium arsenite results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [[Benzene co-treated with Toluene] results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; Buthionine Sulfoximine promotes the reaction [Benzene results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Mercury results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Mercury results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of NQO1 mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of NQO1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA]
Buthionine Sulfoximine results in increased expression of NQO1 mRNA
CTD PMID:16274885 PMID:16906435 PMID:18752316 PMID:20079720 PMID:21971136 More... NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
JBrowse link
G Nr2f2 nuclear receptor subfamily 2, group F, member 2 increases expression EXP Buthionine Sulfoximine results in increased expression of NR2F2 mRNA CTD PMID:15878706 NCBI chr 7:70,001,694...70,016,494
Ensembl chr 7:70,001,692...70,016,483
JBrowse link
G Ntrk1 neurotrophic tyrosine kinase, receptor, type 1 multiple interactions EXP Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein]; Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein; NGF protein affects the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein] CTD PMID:23472850 NCBI chr 3:87,685,551...87,702,549
Ensembl chr 3:87,685,551...87,702,469
JBrowse link
G Nupr1 nuclear protein transcription regulator 1 decreases expression EXP Buthionine Sulfoximine results in decreased expression of NUPR1 mRNA CTD PMID:15878706 NCBI chr 7:126,222,418...126,224,642
Ensembl chr 7:126,222,421...126,230,033
JBrowse link
G Odc1 ornithine decarboxylase, structural 1 increases expression ISO Buthionine Sulfoximine results in increased expression of ODC1 protein CTD PMID:9763232 NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506
JBrowse link
G Ogg1 8-oxoguanine DNA-glycosylase 1 multiple interactions
affects response to substance
EXP Buthionine Sulfoximine affects the reaction [OGG1 protein affects the expression of SOD2 mRNA]
OGG1 protein affects the susceptibility to Buthionine Sulfoximine
CTD PMID:32585298 NCBI chr 6:113,303,959...113,311,149
Ensembl chr 6:113,303,933...113,312,029
JBrowse link
G Orm1 orosomucoid 1 increases expression ISO Buthionine Sulfoximine results in increased expression of ORM1 mRNA; Buthionine Sulfoximine results in increased expression of ORM1 protein CTD PMID:11841787 NCBI chr 4:63,262,793...63,266,400
Ensembl chr 4:63,262,797...63,266,400
JBrowse link
G P4ha1 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 polypeptide decreases expression EXP Buthionine Sulfoximine results in decreased expression of P4HA1 mRNA CTD PMID:15878706 NCBI chr10:59,159,019...59,209,126
Ensembl chr10:59,159,118...59,209,126
JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate affects the cleavage of PARP1 protein]; Buthionine Sulfoximine promotes the reaction [wedelolactone results in increased cleavage of PARP1 protein] CTD PMID:20962031 PMID:22733624 NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic increases expression
multiple interactions
ISO Buthionine Sulfoximine results in increased expression of PCK1 mRNA
SB 203580 inhibits the reaction [Buthionine Sulfoximine results in increased expression of PCK1 mRNA]
CTD PMID:16960379 NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066
JBrowse link
G Pcna proliferating cell nuclear antigen increases expression ISO
EXP
Buthionine Sulfoximine results in increased expression of PCNA protein
Buthionine Sulfoximine results in increased expression of PCNA mRNA
CTD PMID:9763232 PMID:15707499 NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234
JBrowse link
G Pdgfrb platelet derived growth factor receptor, beta polypeptide multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Acetylcysteine inhibits the reaction [Copper Sulfate results in increased expression of PDGFRB mRNA]]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine inhibits the reaction [Copper Sulfate results in increased expression of PDGFRB protein]] CTD PMID:23392711 NCBI chr18:61,178,194...61,218,139
Ensembl chr18:61,178,222...61,218,133
JBrowse link
G Pdia3 protein disulfide isomerase associated 3 increases expression ISO Buthionine Sulfoximine results in increased expression of PDIA3 protein CTD PMID:23736079 NCBI chr 2:121,244,383...121,269,168
Ensembl chr 2:121,244,256...121,269,168
JBrowse link
G Pdk1 pyruvate dehydrogenase kinase, isoenzyme 1 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [Curcumin results in increased phosphorylation of PDK1 protein] CTD PMID:17171638 NCBI chr 2:71,703,398...71,734,202
Ensembl chr 2:71,703,568...71,734,202
JBrowse link
G Pfas phosphoribosylformylglycinamidine synthase (FGAR amidotransferase) increases expression ISO Buthionine Sulfoximine results in increased expression of PFAS protein CTD PMID:23736079 NCBI chr11:68,876,527...68,899,286
Ensembl chr11:68,876,523...68,899,286
JBrowse link
G Phtf1 putative homeodomain transcription factor 1 increases expression EXP Buthionine Sulfoximine results in increased expression of PHTF1 mRNA CTD PMID:15878706 NCBI chr 3:103,875,426...103,914,806
Ensembl chr 3:103,875,426...103,931,914
JBrowse link
G Plxna3 plexin A3 decreases expression EXP Buthionine Sulfoximine results in decreased expression of PLXNA3 mRNA CTD PMID:15878706 NCBI chr  X:73,372,644...73,388,295
Ensembl chr  X:73,372,672...73,388,295
JBrowse link
G Pparg peroxisome proliferator activated receptor gamma multiple interactions
increases expression
EXP
ISO
PPARG mRNA promotes the reaction [Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]]; S-ethyl glutathione inhibits the reaction [Buthionine Sulfoximine results in increased expression of PPARG mRNA]
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of PPARG mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of PPARG protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of PPARG mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of PPARG protein]
CTD PMID:17602960 PMID:21520053 PMID:27358406 NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
JBrowse link
G Ppm1g protein phosphatase 1G (formerly 2C), magnesium-dependent, gamma isoform decreases expression EXP Buthionine Sulfoximine results in decreased expression of PPM1G mRNA CTD PMID:15878706 NCBI chr 5:31,360,012...31,377,889
Ensembl chr 5:31,360,008...31,378,031
JBrowse link
G Ppp3ca protein phosphatase 3, catalytic subunit, alpha isoform increases expression EXP Buthionine Sulfoximine results in increased expression of PPP3CA mRNA CTD PMID:15878706 NCBI chr 3:136,375,778...136,643,488
Ensembl chr 3:136,375,885...136,643,488
JBrowse link
G Ppp5c protein phosphatase 5, catalytic subunit decreases expression EXP Buthionine Sulfoximine results in decreased expression of PPP5C mRNA CTD PMID:15878706 NCBI chr 7:16,738,575...16,761,812
Ensembl chr 7:16,738,565...16,761,849
JBrowse link
G Prdx1 peroxiredoxin 1 increases expression
affects expression
EXP Buthionine Sulfoximine results in increased expression of PRDX1 mRNA
Buthionine Sulfoximine affects the expression of PRDX1 mRNA
CTD PMID:9506838 PMID:15707499 NCBI chr 4:116,542,796...116,557,196
Ensembl chr 4:116,542,741...116,558,019
JBrowse link
G Prim2 DNA primase, p58 subunit decreases expression EXP Buthionine Sulfoximine results in decreased expression of PRIM2 mRNA CTD PMID:15878706 NCBI chr 1:33,492,889...33,708,867
Ensembl chr 1:33,492,891...33,708,876
JBrowse link
G Prkca protein kinase C, alpha decreases activity ISO Buthionine Sulfoximine results in decreased activity of PRKCA protein CTD PMID:11118818 NCBI chr11:107,824,213...108,237,360
Ensembl chr11:107,824,213...108,234,754
JBrowse link
G Prkcb protein kinase C, beta decreases activity ISO Buthionine Sulfoximine results in decreased activity of PRKCB protein CTD PMID:11118818 NCBI chr 7:121,888,327...122,233,625
Ensembl chr 7:121,887,974...122,233,625
JBrowse link
G Prkcd protein kinase C, delta multiple interactions ISO Buthionine Sulfoximine promotes the reaction [Curcumin results in increased phosphorylation of PRKCD protein]
Buthionine Sulfoximine results in increased expression of and results in increased activity of PRKCD protein; Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCD protein]
CTD PMID:11118818 PMID:17171638 NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167
JBrowse link
G Prkce protein kinase C, epsilon multiple interactions ISO Buthionine Sulfoximine results in increased expression of and results in increased activity of PRKCE protein; Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCE protein] CTD PMID:11118818 NCBI chr17:86,472,631...86,965,347
Ensembl chr17:86,475,213...86,965,347
JBrowse link
G Prpf19 pre-mRNA processing factor 19 increases expression ISO Buthionine Sulfoximine results in increased expression of PRPF19 protein CTD PMID:23736079 NCBI chr19:10,872,595...10,886,923
Ensembl chr19:10,872,595...10,886,923
JBrowse link
G Pten phosphatase and tensin homolog multiple interactions EXP Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased degradation of and results in decreased expression of PTEN protein]; Buthionine Sulfoximine promotes the reaction [Cadmium results in increased degradation of and results in decreased expression of PTEN protein] CTD PMID:24449419 NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of PTGS2 mRNA] CTD PMID:23376440 NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
JBrowse link
G Ptk2 PTK2 protein tyrosine kinase 2 increases expression EXP Buthionine Sulfoximine results in increased expression of PTK2 mRNA CTD PMID:15878706 NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129
JBrowse link
G Ptpn1 protein tyrosine phosphatase, non-receptor type 1 increases oxidation ISO Buthionine Sulfoximine results in increased oxidation of PTPN1 protein CTD PMID:20482862 NCBI chr 2:167,772,670...167,821,305
Ensembl chr 2:167,773,977...167,821,305
JBrowse link
G Pttg1 pituitary tumor-transforming gene 1 increases expression EXP Buthionine Sulfoximine results in increased expression of PTTG1 mRNA CTD PMID:15878706 NCBI chr11:43,311,097...43,317,417
Ensembl chr11:43,311,077...43,317,078
JBrowse link
G Rbbp6 retinoblastoma binding protein 6, ubiquitin ligase decreases expression EXP Buthionine Sulfoximine results in decreased expression of RBBP6 mRNA CTD PMID:15878706 NCBI chr 7:122,568,980...122,601,780
Ensembl chr 7:122,564,909...122,601,780
JBrowse link
G Rel reticuloendotheliosis oncogene multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of REL protein] CTD PMID:11970852 PMID:12433058 NCBI chr11:23,686,847...23,720,969
Ensembl chr11:23,686,847...23,720,970
JBrowse link
G Rela v-rel reticuloendotheliosis viral oncogene homolog A (avian) multiple interactions
increases expression
ISO
EXP
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [cinnamaldehyde results in increased glutathionylation of RELA protein]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol results in increased glutathionylation of RELA protein]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein affects the localization of RELA protein]]
Buthionine Sulfoximine results in increased expression of RELA mRNA
Buthionine Sulfoximine affects the reaction [Dextromethorphan affects the activity of RELA protein]; Buthionine Sulfoximine promotes the reaction [Sodium Selenite results in increased expression of RELA mRNA]
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased activity of [NFKB1 protein binds to RELA protein]]
CTD PMID:11970852 PMID:12433058 PMID:18449455 PMID:20116392 PMID:20351055 More... NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
JBrowse link
G Relb avian reticuloendotheliosis viral (v-rel) oncogene related B multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of RELB protein] CTD PMID:11970852 PMID:12433058 NCBI chr 7:19,340,142...19,363,352
Ensembl chr 7:19,340,142...19,363,363
JBrowse link
G Rorc RAR-related orphan receptor gamma increases expression ISO Buthionine Sulfoximine results in increased expression of RORC mRNA CTD PMID:26177832 NCBI chr 3:94,280,106...94,305,583
Ensembl chr 3:94,280,101...94,305,583
JBrowse link
G Rpl10a ribosomal protein L10A increases expression EXP Buthionine Sulfoximine results in increased expression of RPL10A mRNA CTD PMID:15878706 NCBI chr17:28,547,557...28,550,007
Ensembl chr17:28,547,445...28,550,007
JBrowse link
G Rpl12 ribosomal protein L12 increases expression EXP Buthionine Sulfoximine results in increased expression of RPL12 mRNA CTD PMID:15878706 NCBI chr 2:32,851,724...32,854,057
Ensembl chr 2:32,851,571...32,855,357
JBrowse link
G Rpl3 ribosomal protein L3 decreases expression EXP Buthionine Sulfoximine results in decreased expression of RPL3 mRNA CTD PMID:15878706 NCBI chr15:79,961,993...79,967,553
Ensembl chr15:79,961,992...79,976,069
JBrowse link
G Rpl6 ribosomal protein L6 increases expression EXP Buthionine Sulfoximine results in increased expression of RPL6 mRNA CTD PMID:15707499 NCBI chr 5:121,342,564...121,347,304
Ensembl chr 5:121,342,544...121,347,304
JBrowse link
G Rpl8 ribosomal protein L8 increases expression EXP Buthionine Sulfoximine results in increased expression of RPL8 mRNA CTD PMID:15878706 NCBI chr15:76,788,271...76,790,518
Ensembl chr15:76,788,278...76,790,514
JBrowse link
G Rplp0 ribosomal protein lateral stalk subunit P0 increases expression EXP Buthionine Sulfoximine results in increased expression of RPLP0 mRNA CTD PMID:15878706 NCBI chr 5:115,697,526...115,701,788
Ensembl chr 5:115,697,526...115,701,786
JBrowse link
G Rplp1 ribosomal protein lateral stalk subunit P1 increases expression EXP Buthionine Sulfoximine results in increased expression of RPLP1 mRNA CTD PMID:15878706 NCBI chr 9:61,820,565...61,821,792
Ensembl chr 9:61,820,566...61,821,824
JBrowse link
G Rps12 ribosomal protein S12 increases expression EXP Buthionine Sulfoximine results in increased expression of RPS12 mRNA CTD PMID:15878706 NCBI chr10:23,661,042...23,664,297
Ensembl chr10:23,661,081...23,663,173
JBrowse link
G Rps14 ribosomal protein S14 increases expression EXP Buthionine Sulfoximine results in increased expression of RPS14 mRNA CTD PMID:15878706 NCBI chr18:60,907,668...60,911,618
Ensembl chr18:60,880,170...60,911,618
JBrowse link
G Rps15 ribosomal protein S15 increases expression EXP Buthionine Sulfoximine results in increased expression of RPS15 mRNA CTD PMID:15878706 NCBI chr10:80,128,265...80,129,948
Ensembl chr10:80,128,287...80,129,948
JBrowse link
G Rps20 ribosomal protein S20 increases expression EXP Buthionine Sulfoximine results in increased expression of RPS20 mRNA CTD PMID:15878706 NCBI chr 4:3,831,334...3,835,600
Ensembl chr 4:3,831,334...3,835,665
JBrowse link
G Rps26 ribosomal protein S26 increases expression EXP Buthionine Sulfoximine results in increased expression of RPS26 mRNA CTD PMID:15878706 NCBI chr10:128,460,398...128,462,375
Ensembl chr10:128,460,403...128,462,616
JBrowse link
G Rps6 ribosomal protein S6 increases expression EXP Buthionine Sulfoximine results in increased expression of RPS6 mRNA CTD PMID:15878706 NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649
JBrowse link
G Rps7 ribosomal protein S7 increases expression EXP Buthionine Sulfoximine results in increased expression of RPS7 mRNA CTD PMID:15878706 NCBI chr12:28,680,846...28,685,952
Ensembl chr12:28,680,853...28,685,952
JBrowse link
G Rps8 ribosomal protein S8 increases expression EXP Buthionine Sulfoximine results in increased expression of RPS8 mRNA CTD PMID:15878706 NCBI chr 4:117,011,033...117,013,329
Ensembl chr 4:117,011,024...117,013,440
JBrowse link
G S100a8 S100 calcium binding protein A8 (calgranulin A) multiple interactions EXP
ISO
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A8 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A8 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A8 mRNA]
CTD PMID:23986454 PMID:26177832 PMID:28263783 PMID:30853469 PMID:31294483 NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342
JBrowse link
G S100a9 S100 calcium binding protein A9 (calgranulin B) multiple interactions EXP
ISO
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A9 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA; [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of S100A9 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A9 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A9 mRNA]
CTD PMID:23986454 PMID:26177832 PMID:28263783 PMID:29154782 PMID:30853469 More... NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028
JBrowse link
G Sele selectin, endothelial cell multiple interactions ISO [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of SELE mRNA] CTD PMID:21971136 NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
JBrowse link
G Selenow selenoprotein W decreases expression
multiple interactions
ISO Buthionine Sulfoximine results in decreased expression of SELENOW mRNA
[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased expression of SELENOW mRNA
CTD PMID:15823556 NCBI chr 7:15,651,133...15,656,296
Ensembl chr 7:15,651,133...15,656,327
JBrowse link
G Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N decreases expression EXP Buthionine Sulfoximine results in decreased expression of SERPINA3N mRNA CTD PMID:15707499 NCBI chr12:104,372,967...104,380,588
Ensembl chr12:104,372,988...104,380,588
JBrowse link
G Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 increases expression ISO Buthionine Sulfoximine results in increased expression of SERPINE1 mRNA CTD PMID:23939143 NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
JBrowse link
G Sesn2 sestrin 2 increases expression ISO Buthionine Sulfoximine results in increased expression of SESN2 protein CTD PMID:31323261 NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812
JBrowse link
G Shank3 SH3 and multiple ankyrin repeat domains 3 decreases expression EXP Buthionine Sulfoximine results in decreased expression of SHANK3 mRNA CTD PMID:15878706 NCBI chr15:89,376,929...89,444,464
Ensembl chr15:89,383,826...89,444,464
JBrowse link
G Siah2 siah E3 ubiquitin protein ligase 2 decreases expression EXP Buthionine Sulfoximine results in decreased expression of SIAH2 mRNA CTD PMID:15878706 NCBI chr 3:58,582,370...58,599,857
Ensembl chr 3:58,582,359...58,599,821
JBrowse link
G Slc31a1 solute carrier family 31, member 1 multiple interactions ISO [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [SLC31A1 protein results in increased import of Copper]; Buthionine Sulfoximine inhibits the reaction [SLC31A1 protein results in increased import of Copper]; glutathione diethyl ester inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [SLC31A1 protein results in increased import of Copper]] CTD PMID:23426973 NCBI chr 4:62,278,821...62,310,006
Ensembl chr 4:62,278,964...62,310,006
JBrowse link
G Snca synuclein, alpha increases expression ISO Buthionine Sulfoximine results in increased expression of SNCA protein CTD PMID:15114628 NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839
JBrowse link
G Snta1 syntrophin, acidic 1 decreases expression EXP Buthionine Sulfoximine results in decreased expression of SNTA1 mRNA CTD PMID:15878706 NCBI chr 2:154,218,234...154,250,004
Ensembl chr 2:154,218,233...154,250,019
JBrowse link
G Sod1 superoxide dismutase 1, soluble increases expression EXP Buthionine Sulfoximine results in increased expression of SOD1 mRNA CTD PMID:15707499 NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
JBrowse link
G Sod2 superoxide dismutase 2, mitochondrial multiple interactions
increases response to substance
ISO
EXP
[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]
SOD2 protein results in increased susceptibility to Buthionine Sulfoximine
Buthionine Sulfoximine affects the reaction [OGG1 protein affects the expression of SOD2 mRNA]
CTD PMID:8877099 PMID:10464329 PMID:15130278 PMID:32585298 NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
JBrowse link
G Sord sorbitol dehydrogenase multiple interactions EXP Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased secretion of SORD protein] CTD PMID:12763371 NCBI chr 2:122,065,320...122,095,818
Ensembl chr 2:122,065,230...122,095,821
JBrowse link
G Sox4 SRY (sex determining region Y)-box 4 multiple interactions EXP [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of SOX4 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of SOX4 protein CTD PMID:27421576 NCBI chr13:29,132,902...29,137,682
Ensembl chr13:29,132,902...29,137,696
JBrowse link
G Sp1 trans-acting transcription factor 1 increases activity
multiple interactions
ISO Buthionine Sulfoximine results in increased activity of SP1 protein
mithramycin A inhibits the reaction [Buthionine Sulfoximine results in increased activity of SP1 protein]
CTD PMID:11261509 NCBI chr15:102,314,751...102,344,839
Ensembl chr15:102,314,578...102,344,839
JBrowse link
G Sp3 trans-acting transcription factor 3 multiple interactions
increases activity
ISO mithramycin A inhibits the reaction [Buthionine Sulfoximine results in increased activity of SP3 protein] CTD PMID:11261509 NCBI chr 2:72,766,774...72,810,790
Ensembl chr 2:72,766,771...72,810,790
JBrowse link
G Spp1 secreted phosphoprotein 1 decreases expression EXP Buthionine Sulfoximine results in decreased expression of SPP1 mRNA CTD PMID:15707499 PMID:15878706 NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression ISO Buthionine Sulfoximine results in decreased expression of SREBF1 mRNA CTD PMID:20482862 NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
JBrowse link
G Srebf2 sterol regulatory element binding factor 2 multiple interactions EXP Buthionine Sulfoximine inhibits the reaction [Metformin inhibits the reaction [Hydrogen Peroxide results in increased cleavage of SREBF2 protein]]; Buthionine Sulfoximine promotes the reaction [Hydrogen Peroxide results in increased cleavage of SREBF2 protein] CTD PMID:29499335 NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580
JBrowse link
G Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) increases expression EXP Buthionine Sulfoximine results in increased expression of SRXN1 protein CTD PMID:27358234 NCBI chr 2:151,946,738...151,953,296
Ensembl chr 2:151,947,436...151,953,296
JBrowse link
G Stat3 signal transducer and activator of transcription 3 increases activity
increases expression
multiple interactions
ISO
EXP
Buthionine Sulfoximine results in increased activity of STAT3 protein
Buthionine Sulfoximine results in increased expression of STAT3 mRNA
[Troglitazone co-treated with Buthionine Sulfoximine] results in increased phosphorylation of STAT3 protein
CTD PMID:11841787 PMID:31294483 NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
JBrowse link
G Syn1 synapsin I increases expression EXP Buthionine Sulfoximine results in increased expression of SYN1 mRNA CTD PMID:15878706 NCBI chr  X:20,726,750...20,787,157
Ensembl chr  X:20,726,750...20,787,243
JBrowse link
G Syp synaptophysin multiple interactions ISO (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein CTD PMID:19850110 NCBI chr  X:7,504,819...7,519,495
Ensembl chr  X:7,504,710...7,519,495
JBrowse link
G Tbca tubulin cofactor A increases expression EXP Buthionine Sulfoximine results in increased expression of TBCA mRNA CTD PMID:15878706 NCBI chr13:94,925,428...94,979,431
Ensembl chr13:94,925,418...94,979,430
JBrowse link
G Tbx21 T-box 21 multiple interactions EXP [Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TBX21 mRNA CTD PMID:23986454 NCBI chr11:96,988,833...97,006,157
Ensembl chr11:96,988,897...97,006,157
JBrowse link
G Tgfbr1 transforming growth factor, beta receptor I multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR1 protein] CTD PMID:17602960 NCBI chr 4:47,353,258...47,414,926
Ensembl chr 4:47,353,222...47,414,931
JBrowse link
G Tgfbr2 transforming growth factor, beta receptor II multiple interactions ISO Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR2 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR2 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR2 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR2 protein] CTD PMID:17602960 NCBI chr 9:115,916,763...116,004,431
Ensembl chr 9:115,913,361...116,004,428
JBrowse link
G Thrsp thyroid hormone responsive decreases expression ISO Buthionine Sulfoximine results in decreased expression of THRSP mRNA CTD PMID:20482862 NCBI chr 7:97,062,140...97,066,757
Ensembl chr 7:97,062,145...97,066,937
JBrowse link
G Tinf2 Terf1 (TRF1)-interacting nuclear factor 2 increases expression EXP Buthionine Sulfoximine results in increased expression of TINF2 mRNA CTD PMID:15878706 NCBI chr14:55,912,120...55,919,265
Ensembl chr14:55,912,146...55,919,277
JBrowse link
G Tle5 TLE family member 5, transcriptional modulator increases expression EXP Buthionine Sulfoximine results in increased expression of TLE5 mRNA CTD PMID:15878706 NCBI chr10:81,395,278...81,402,205
Ensembl chr10:81,395,322...81,402,196
JBrowse link
G Tlr2 toll-like receptor 2 multiple interactions EXP [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of TLR2 mRNA CTD PMID:23986454 NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP
ISO
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR4 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TLR4 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TLR4 protein]
CTD PMID:23986454 PMID:26177832 NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
JBrowse link
G Tlr9 toll-like receptor 9 multiple interactions EXP [Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR9 mRNA CTD PMID:23986454 NCBI chr 9:106,099,797...106,104,075
Ensembl chr 9:106,099,797...106,104,082
JBrowse link
G Tmsb10 thymosin beta 10 increases expression EXP Buthionine Sulfoximine results in increased expression of TMSB10 mRNA CTD PMID:15707499 NCBI chr 6:72,934,330...72,935,731
Ensembl chr 6:72,934,330...72,935,731
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases secretion
ISO
EXP
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased susceptibility to TNF protein]; [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which co-treated with arsenite] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased susceptibility to TNF protein; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of TNF protein]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TNF mRNA; [Carmustine co-treated with Buthionine Sulfoximine] inhibits the reaction [TNF protein results in increased expression of NOS2 protein]; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of TNF protein]; Buthionine Sulfoximine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]; Buthionine Sulfoximine promotes the reaction [Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Buthionine Sulfoximine]
[pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of TNF mRNA; Buthionine Sulfoximine inhibits the reaction [manganese chloride promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]]
CTD PMID:7532384 PMID:11167962 PMID:11970852 PMID:12433058 PMID:15601679 More... NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
JBrowse link
G Top2b topoisomerase (DNA) II beta decreases expression EXP Buthionine Sulfoximine results in decreased expression of TOP2B mRNA CTD PMID:15707499 NCBI chr14:6,038,976...6,104,585
Ensembl chr14:6,034,301...6,104,584
JBrowse link
G Tpi1 triosephosphate isomerase 1 increases expression ISO Buthionine Sulfoximine results in increased expression of TPI1 protein CTD PMID:23736079 NCBI chr 6:124,787,549...124,791,121
Ensembl chr 6:124,787,549...124,791,259
JBrowse link
G Trap1 TNF receptor-associated protein 1 increases expression ISO Buthionine Sulfoximine results in increased expression of TRAP1 protein CTD PMID:23736079 NCBI chr16:3,857,835...3,895,704
Ensembl chr16:3,857,835...3,895,691
JBrowse link
G Trp53 transformation related protein 53 multiple interactions
increases expression
ISO
EXP
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [Benzo(a)pyrene results in increased activity of TP53 protein]
Buthionine Sulfoximine results in increased expression of TRP53 protein
[cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased expression of TP53 protein
CTD PMID:12807757 PMID:18552690 PMID:25410294 NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
JBrowse link
G Trpm2 transient receptor potential cation channel, subfamily M, member 2 multiple interactions EXP 4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; [Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein; Glutathione inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein] CTD PMID:33309544 NCBI chr10:77,743,556...77,805,746
Ensembl chr10:77,743,556...77,806,397
JBrowse link
G Trpv4 transient receptor potential cation channel, subfamily V, member 4 multiple interactions ISO [Gadolinium results in decreased activity of TRPV4 protein] which results in decreased susceptibility to Buthionine Sulfoximine; [Ruthenium Red results in decreased activity of TRPV4 protein] which results in decreased susceptibility to Buthionine Sulfoximine CTD PMID:20064552 NCBI chr 5:114,760,213...114,796,497
Ensembl chr 5:114,760,213...114,796,482
JBrowse link
G Txn1 thioredoxin 1 increases expression
multiple interactions
EXP Buthionine Sulfoximine results in increased expression of TXN1 mRNA
NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of TXN1 mRNA]
CTD PMID:23472850 NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions
increases expression
increases response to substance
ISO
EXP
Buthionine Sulfoximine inhibits the reaction [sulforaphane results in increased expression of TXNRD1 mRNA]; Buthionine Sulfoximine promotes the reaction [Sodium Selenite results in increased activity of TXNRD1 protein]
Buthionine Sulfoximine results in increased expression of TXNRD1 mRNA
[Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of TXNRD1 protein
TXNRD1 gene mutant form results in increased susceptibility to Buthionine Sulfoximine
CTD PMID:12663510 PMID:16288907 PMID:19010381 PMID:24853413 NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546
JBrowse link
G U2af2 U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 2 increases expression ISO Buthionine Sulfoximine results in increased expression of U2AF2 protein CTD PMID:23736079 NCBI chr 7:5,063,884...5,082,937
Ensembl chr 7:5,065,142...5,082,937
JBrowse link
G Ubc ubiquitin C increases expression EXP Buthionine Sulfoximine results in increased expression of UBC mRNA CTD PMID:15878706 NCBI chr 5:125,463,029...125,467,081
Ensembl chr 5:125,463,029...125,467,266
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO
EXP
[[Buthionine Sulfoximine results in decreased abundance of Glutathione] which co-treated with arsenite] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]
[Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of VCAM1 mRNA
CTD PMID:16271621 PMID:21971136 PMID:31294483 NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of VEGFA mRNA] CTD PMID:11641398 NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
JBrowse link
G Vps26c VPS26 endosomal protein sorting factor C decreases expression EXP Buthionine Sulfoximine results in decreased expression of VPS26C mRNA CTD PMID:15878706 NCBI chr16:94,298,583...94,327,488
Ensembl chr16:94,298,642...94,327,689
JBrowse link
G Xirp1 xin actin-binding repeat containing 1 multiple interactions EXP [Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of XIRP1 mRNA CTD PMID:29679711 NCBI chr 9:119,842,821...119,852,660
Ensembl chr 9:119,842,821...119,852,664
JBrowse link
G Zfp422 zinc finger protein 422 decreases expression EXP Buthionine Sulfoximine results in decreased expression of ZFP422 mRNA CTD PMID:15878706 NCBI chr 6:116,600,977...116,605,960
Ensembl chr 6:116,600,977...116,605,960
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 22188
    role 22173
      biological role 22172
        biochemical role 21436
          ferroptosis inducer 16323
            S-butyl-DL-homocysteine (S,R)-sulfoximine 343
Path 2
Term Annotations click to browse term
  CHEBI ontology 22188
    subatomic particle 22180
      composite particle 22180
        hadron 22180
          baryon 22180
            nucleon 22180
              atomic nucleus 22180
                atom 22180
                  main group element atom 22114
                    p-block element atom 22114
                      carbon group element atom 21915
                        carbon atom 21840
                          organic molecular entity 21840
                            organic group 20283
                              organic divalent group 20165
                                organodiyl group 20165
                                  carbonyl group 20159
                                    carbonyl compound 20159
                                      carboxylic acid 19557
                                        amino acid 16426
                                          alpha-amino acid 14221
                                            non-proteinogenic alpha-amino acid 3838
                                              homocysteines 438
                                                2-amino-4-(S-butylsulfonimidoyl)butanoic acid 343
                                                  D-buthionine-(S,R)-sulfoximine 343
                                                    S-butyl-DL-homocysteine (S,R)-sulfoximine 343
paths to the root